Neighborhood Police Complaints Tied to Black Preterm Birth Rates medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Clinical trials of new treatments for COVID-19 often do not include vulnerable populations
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine.
This study highlights the blind spot in how clinical trials are done in the United States. Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people.
E-Mail
Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.
The findings, based on an analysis of all US COVID-19 treatment trials registered on ClinicalTrials.gov, were published Jan. 27 in the
Journal of General Internal Medicine. This study highlights the blind spot in how clinical trials are done in the United States, said senior author Neda Laiteerapong, MD, MS, a general internist and associate director of the Center for Chronic Disease Research and Policy at the University of Chicago. Researchers, hospitals and pharmaceutical companies need to think hard about their commitment to improving the health of all people.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today announced the formation of the AMP COVID Response (ACR) Steering Committee to help coordinate and communicate the organization's continued efforts to guide diagnostic testing during the ongoing COVID-19 pandemic and preparations for future emerging outbreaks.
E-Mail
ROCKVILLE, Md. - Jan. 26, 2021 - The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today announced the formation of the AMP COVID Response (ACR) Steering Committee to help coordinate and communicate the organization s continued efforts to guide diagnostic testing during the ongoing COVID-19 pandemic and preparations for future emerging outbreaks. Committee members will share expertise and provide recommendations to key stakeholders, including the incoming Biden administration, to help address the many challenges facing healthcare providers and ensure more Americans have timely access to high-quality testing. Timely diagnostic testing is foundational to an effective response to any emerging communicable disease. AMP members have been on the frontlines of this pandemic and have been responsible for managing the ever-increasing demand for testing despite numerous regulatory, reimbursement, supply-chain, logistical,